

Date of submission: 20th May, 2022

To, The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 539551	To, The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051 Scrip Code- NH
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Sub: Press Release for the Financial Year ended 31st March, 2022 and Call invite

With reference to the subject, please find enclosed Press Release for the Financial Year ended 31st March, 2022 and call invite to discuss the Company's performance on 23rd May, 2022 at 02:30 P.M. (IST).

Kindly take the above information on record.

Thanking you.

Yours faithfully
For **Narayana Hrudayalaya Limited**



Sridhar S
Group Company Secretary, Legal & Compliance Officer

Encl.: as above

**Q4 FY22 Consolidated operating income at Rs 9,407 mn (Y-o-Y of 12.3%) with EBITDA* of Rs 1,848 mn (Y-o-Y of 23.3%)
FY22 Consolidated operating income at Rs 37,013 mn (Y-o-Y of 43.3%) with EBITDA* of Rs 6,881 mn (Y-o-Y of 227.2%)**

Bengaluru, India, May 20th, 2022 – Narayana Hrudayalaya Limited, a leading healthcare service provider in India, today announced its financial results for the fourth quarter (Q4 FY22) ended March 31st, 2022.

Financial Highlights for the Quarter (Q4 FY22) - Prepared in accordance with Ind AS ('Indian Accounting Standards')

- Consolidated total operating income was Rs 9,407 mn for Q4 FY22 as compared to Rs 8,379 mn in Q4 FY21 reflecting an YoY growth of 12.3%
- Consolidated EBITDA* stood at Rs 1,848 mn, reflecting a margin of 19.6% as against Rs 1,499 mn in Q4 FY21, translating into a YoY growth of 23.3%
- Consolidated PAT* stood at Rs 690 mn, reflecting a margin of 7.3% as compared to Rs 681 mn in Q4 FY 21 reflecting an YoY growth of over 1.3%

Financial Highlights for the Twelve Months (FY22)

- Consolidated total operating income was Rs 37,013 mn for FY22 as compared to Rs 25,830 mn in FY 21
- Consolidated EBITDA* of Rs 6,881 mn for FY22, reflecting a margin of 18.6% as against Rs 2,103 mn in FY 21
- Consolidated PAT* stood at Rs 3,421 mn for FY22, reflecting a margin of 9.2% as compared to loss of Rs 143 mn in FY 21

** This is as per the new accounting treatment for leases per IND AS 116 effective 1st April 2019 which resulted in Rs 116 mn increase in EBITDA and decrease of Rs 18 mn in PAT for Q4 FY 22 and Rs 547 mn increase in EBITDA and decrease of Rs 25 mn in PAT for FY22 on a like-to-like basis (pre-IND AS 116)*

As on March 31st, 2022, the Total Borrowings less Cash & Bank Balance and Current Investments was Rs. 2,415 mn representing a net debt to equity ratio of 0.16. (Out of which, borrowings worth US\$ 30.0 mn is foreign currency denominated).

Other Highlights during the Quarter

- Dharamshila Narayana Superspeciality Hospital, Delhi became the first hospital globally to implement total body irradiation (TBI) technique on Halcyon LINAC for a case of aplastic anaemia
- Rabindranath Tagore International Institute of Cardiac Sciences (RTIICS), Kolkata successfully performed certain cutting-edge image guided procedures in Interventional Radiology & Interventional Neurology in the quarter such as
 - Interventional Radiology - Cryoablation in Renal Cell Carcinoma (RCC) and Thoracic endovascular aortic repair (TEVAR) with carotid-carotid and left carotid-subclavian artery bypass grafting
 - Interventional Neurology - Flow diverter assisted coiling in acutely ruptured aneurysm and percutaneous embolization of scalp arteriovenous malformation (AVM)
- Mazumdar Shaw Medical Centre (MSMC), Bengaluru commissioned hyperbaric oxygen therapy unit in the quarter; the unit also successfully conducted 63 bone marrow transplants (BMT) during this period

Management Comment

Commenting on the performance, **Dr. Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya Limited**, said *"Having surpassed the pre-Covid highs of profitability for the 1st time post the onset of the pandemic in the previous quarter after the gradual recovery witnessed post the second wave, our Indian operations were significantly impacted during Q4 FY 22 due to the third wave induced disruptions. While this did result in an QoQ decline in the profitability of our Indian operations with Q4 historically being the strongest quarter for the domestic business, we are pleased to have ended the year on a strong footing with the recovery witnessed in the month of March, 2022. Our consolidated profitability for the quarter was aided by our international ventures at Cayman Islands and hospital project management at St. Lucia.*

Overall, despite the severe challenges faced during the year gone by, we are pleased to have made a strong comeback post the almost washout in the previous fiscal and have further fortified our balance sheet and continue to maintain a strong liquidity profile with best in class return ratios. Looking ahead, we look to sustain the business momentum notwithstanding Covid-19 related uncertainties."

About Narayana Hrudayalaya Limited

Founded in 2000 by Dr. Devi Prasad Shetty and headquartered in Bengaluru, Narayana Hrudayalaya Limited is one of the leading healthcare service providers in India, operating a chain of multispecialty, tertiary, and primary healthcare facilities. The Company has a network of 20 hospitals and 4 heart centres across India along with overseas presence across a hospital at Cayman Islands and a managed hospital at St. Lucia with over 6,000 operational beds across all its centres & potential to reach a capacity of over 6,500 beds.

For further details, please contact us at investorrelations@narayanahealth.org

Q4 FY22 Result Conference Call

At 2:30 PM, IST on May 23rd, 2022

Following the announcement of the fourth quarter (Q4 FY22) ended March 31st, 2022 results on May 20th, 2022, the management of Narayana Hrudayalaya Limited will host a conference call to discuss the Company's performance on May 23rd, 2022 at 2:30 pm IST.

Details of the conference call are as under:

Date:	Monday, May 23 rd , 2022
Time:	2:30 pm IST
Dial-in Details:	
Click on the URL	https://narayanahealth-org.zoom.us/j/81761670709?pwd=UFIVZVBnSVJRaDBoRkV6U01hMS9mUT09 Meeting ID: 817 6167 0709 Passcode: 996321
Transcript	The transcript will be uploaded on our website www.narayanahealth.org